Despite its powerful presence in Washington, D.C., pharma took a surprise hit last week when the Senate's budget deal forced bigger contributions in Medicare Part D's coverage gap. But most drugmakers won't take much of a hit, analysts said Monday. Who will? Companies heavily invested in diabetes and COPD.Original Article
Pharma will pay more under the new budget deal—and some long-suffering pharmas will pay the most
